Clinical Trial

Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen

Study acronym: AUSTRAL
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Aim of this phase 2 study is to explore the safety and efficacy of thoracic re-irradiation +/- SBRT to oligometastases (\<3) followed after an interval of 2 weeks by durvalumab and ceralasertib for patients with thoracic relapses +/- oligometastases after PACIFIC or PACIFIC-like (concurrent or sequential chemo-radiotherapy followed by maintenance durvalumab) regimens.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-06.
Status change: Not Yet Recruiting → Recruiting 2025-12-10
Trial Details
NCT Number NCT06680050
Lead Sponsor Mario Negri Institute for Pharmacological Research
Conditions Non Small Cell Lung Cancer NSCLC
Enrollment 21 participants
Start Date 2025-08-07
Primary Completion 2028-06 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-18